Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
Following the report, several state legislators – including Carr, K.C. Ohaebosim, Henry Helgerson, Susan Estes, Angela ...
N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...
A harbor seal and a Chilean flamingo at the Lincoln Park Zoo died as a result of avian influenza last week, zoo officials ...
This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...
Medical supply chain experts have previously said Trump’s proposed tariffs would likely cause the price of imported drugs to go up. Still, there are several factors at play when it comes to ...
Wells Fargo analyst Larry Biegelsen has maintained their neutral stance on JNJ stock, giving a Hold rating yesterday.Stay Ahead of the ...
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
To Luis Roman, vice president of MedTech Supply Chain at Johnson & Johnson, the digital journey represents more than just improving supply chain operations. “For us, digital innovation is viewed as an ...
WASHINGTON – House Republicans gave Mike Johnson the speaker's gavel on Friday – along with a warning. Nine GOP lawmakers at first either abstained from voting for Johnson or voted for a ...